Telix Pharmaceuticals

Anteris Technologies' shares trade on Nasdaq at a 12% discount, raising ~US$88M for Duravr valve development. Anatara Lifesciences pauses IBS trial recruitment with sufficient participants. 4D Medical secures another US lung imaging contract with University of Chicago Medicine.

Adenosine antagonists market growth driven by R&D in neurodegenerative diseases, oncology, and cardiovascular disorders. Innovations in formulation and delivery systems enhance efficacy and safety, increasing adoption. Key companies include Arcus Biosciences, Corvus Pharmaceuticals, Portage Biotech, Palobiofarm, iTeos Therapeutics. Promising drugs like Etrumadenant, Ciforadenant, PORT-6, and Inupadenant are in various clinical trial phases.

Explore Smartkarma's AI-augmented investing platform with a free Preview Pass to unlock research summaries, follow top analysts, receive personalized alerts, and access analytics and events. Join over 55,000 investors, including top global asset managers, and upgrade to paid plans later.

Telix Pharmaceuticals, in collaboration with Grand Pharmaceutical Group, has dosed the first patient in China for its Phase III ZIRCON-CP trial of TLX250-CDx, a PET imaging agent for clear cell renal cell carcinomas. The trial aims to support previous global Phase III ZIRCON trial results and demonstrate TLX250-CDx's efficacy in Chinese populations.

Doctors in Perth initiate ProstACT GLOBAL, a multinational Phase 3 trial sponsored by Telix Pharmaceuticals, investigating a radio antibody-drug conjugate (rADC) for advanced prostate cancer. The rADC targets prostate-specific membrane antigen (PSMA) to selectively irradiate tumor cells. Led by Dr. Aviral Singh at St John of God Murdoch Hospital, the trial aims to evaluate efficacy, safety, and quality of life, building on previous Phase 1 and 2 studies.

Telix Pharmaceuticals benefits from US reimbursement for high-value radiopharmaceuticals, ensuring continued separate payment for Illucix. Optiscan collaborates with Monash University to develop a next-gen endomicroscope integrating AI. BOD Australia investors await a vote on a back-door merger.

Telix Pharmaceuticals benefits from US reimbursement for high-value radiopharmaceuticals, Optiscan collaborates with Monash University for next-gen endomicroscope development involving AI, and BOD Australia investors await vote on back-door merger.

Telix Pharmaceuticals Ltd shares rise 3% to $22.12 after CMS announces separate payments for specialized diagnostic radiopharmaceuticals, facilitating equitable access for Medicare Fee for Service patients. The new payment rule, based on Mean Unit Cost, will apply to Telix's Illuccix and pipeline products from July 2025, ensuring consistent reimbursement.

Telix Pharmaceuticals welcomes CMS' decision to unbundle payments for diagnostic radiopharmaceuticals, enabling decisions based on diagnostic tools rather than reimbursement structure. The changes will apply to Telix's prostate cancer imaging product Illuccix from July 2025, promoting investment in new imaging agents.